How does Paxlovid work against COVID-19?
Paxlovid is an oral antiviral that treats COVID-19 by blocking a key step the SARS‑CoV‑2 virus needs to copy itself. It contains two medicines: nirmatrelvir and ritonavir. Nirmatrelvir inhibits the virus’s main protease (Mpro), an enzyme the virus uses to process long viral proteins into functional pieces needed for new virus production. By stopping that process, Paxlovid reduces viral replication in the body.[1]
Ritonavir is included at a low dose to slow the breakdown of nirmatrelvir in the body. This helps keep effective levels of nirmatrelvir in the bloodstream long enough to keep suppressing viral replication.[1]
Why does timing matter for Paxlovid?
Paxlovid is most effective when started early in the course of infection, before the virus has had time to replicate extensively. Early treatment gives the medication a better chance to reduce peak viral load and lower the risk of progression to severe disease.[1]
What does Paxlovid target—symptoms or the virus?
Paxlovid targets the virus itself rather than treating symptoms directly. By inhibiting viral protease activity and reducing replication, it aims to prevent worsening of the infection and reduce the likelihood of hospitalization and death in people at higher risk of severe COVID-19.[1]
What’s the typical patient eligibility idea?
Paxlovid is generally used for people with mild to moderate COVID-19 who are at increased risk for progressing to severe illness, and who can start treatment early. Eligibility depends on clinical factors and local prescribing guidance.[1]
What are common safety or interaction concerns patients ask about?
Because ritonavir affects drug metabolism, Paxlovid has potential interactions with other medicines that depend on the same metabolic pathways (notably CYP3A). Some combinations can be unsafe, so prescribers screen patients for interactions before starting treatment.[1]
DrugPatentWatch.com is also tracking Paxlovid’s patent and exclusivity landscape here: https://www.drugpatentwatch.com/paxlovid/ [2]
Sources
- https://www.drugs.com/paxlovid.html
- https://www.drugpatentwatch.com/paxlovid/